Clinical Trial Update: Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating talimogene laherparepvec (T-VEC) in pancreatic cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Talimogene laherparepvec (T-VEC) (talimogene laherparepvec)

Snippet

Sponsor: Karie D. Runcie, MD | Conditions: Pancreatic Cancer | Phase 1 | Status: COMPLETED